E-ISSN 2757-8062
Volume : 57 Issue : 1 Year : 2026

Quick Search

Therapeutic curettage as a safe and effective first-line approach in cesarean scar pregnancy: A single-center comparative analysis with the literature [Zeynep Kamil Med J]
Zeynep Kamil Med J. 2026; 57(1): 7-10 | DOI: 10.14744/zkmj.2025.48726

Therapeutic curettage as a safe and effective first-line approach in cesarean scar pregnancy: A single-center comparative analysis with the literature

Burak Güler1, Burak Hazine2, Onuralp Bilgin3, Resul Karakuş3
1Department of Obstetrics and Gynecology, Acibadem Altunizade Hospital, Istanbul, Turkey
2Department of Obstetrics and Gynecology, Liv Hospital Vadistanbul, Istanbul, Turkey
3Department of Obstetrics and Gynecology, Zeynep Kamil Women and Children's Diseases Training and Research Hospital, Istanbul, Turkey

INTRODUCTION: Cesarean scar pregnancy (CSP) is a rare ectopic pregnancy implanted in a previous cesarean scar and is associated with risks of hemorrhage, uterine rupture, and infertility. Rising cesarean rates have increased its incidence, accounting for up to 6% of ectopic pregnancies. Diagnosis is made by transvaginal ultrasound, which typically shows an empty uterine cavity and a gestational sac at the anterior isthmus with thin myometrium. Treatment options include methotrexate, uterine artery embolization, hysteroscopic or laparoscopic excision, and curettage. No consensus standard exists; management should be individualized.
METHODS: We retrospectively analyzed 129 CSP patients treated between 2015 and 2025 at Zeynep Kamil Hospital, Istanbul. Inclusion required an ultrasound-confirmed diagnosis and complete hematologic data. Patients managed conservatively or with incomplete records were excluded. Treatment included primary curettage, methotrexate plus curettage, or laparoscopic repair. Curettage was ultrasound-guided using a Karman cannula. Hemoglobin and hematocrit levels were compared pre- and postoperatively, and transfusion needs were documented.
RESULTS: Of the 129 patients, 123 (95.4%) underwent curettage, 3 underwent methotrexate plus curettage, and 3 underwent laparoscopic repair. The mean hemoglobin drop was 0.8 g/dL (p<0.001), and the mean hematocrit decrease was 2.2% (p<0.001). Only 3 patients (2.3%) required transfusion. Subgroup analysis showed greater hemoglobin decline in patients with a gestational age ≥8 weeks and fetal cardiac activity. Compared with the literature reporting larger declines and higher transfusion rates, our outcomes were favorable.
DISCUSSION AND CONCLUSION: Ultrasound-guided therapeutic curettage is a safe, effective, and fertility-preserving first-line treatment for CSP. It achieved low blood loss and minimal transfusion requirements compared with prior reports. Despite the retrospective design and lack of long-term follow-up, our results support curettage as a reliable option in appropriately selected patients.

Keywords: Blood transfusion, cesarean scar pregnancy, ectopic pregnancy, hemoglobin drop, therapeutic curettage, ultrasound-guided aspiration.


Corresponding Author: Burak Güler, Türkiye
Manuscript Language: English
×
APA
NLM
AMA
MLA
Chicago
Copied!
CITE
LookUs & Online Makale